摘要：

Objective To investigate the effect of loading dose atorvastatin on myocardial injury and inflammatory reaction in patients with non-ST segment elevation acute coronary syndromes (ACS)undergoing early percutaneous coronary intervention.Methods A total of 81 patients with non-ST segment elevation ACS were randomized to pretreatment with atorvastatin (80 mg 12 h before PCI,with a further 40 mg preprocedure dose (n=41) or placebo group(n=40),CK-MB,cTnI,hs-CRP,CK and ALT/AST of the blood from elbow vein were monitored before and 8 and 24 hours after the procedure of PCI.The main end point of the trial was a 30-day incidence of major adverse cardiac events.Results The markers of two groups were elevated after PCI,however,the ascended values of CK-MB,cTnI,hs-CRP in the atorvastatin treatment group were significantly lower than those of the placebo group(P0.01).the major adverse cardiacb events occurred in 2.4% of patients in the atorvastatin group and 22.5% of those in the placebo group (P=0.0161).This difference was mostly driven by reduction of myocardial infarction incidence (2.4% vs 20.0%)(P=0.0307).Conclusion even short-term pretreatment with high dose atorvastatin may improve outcomes in patients with non-ST segment ACS undergoing early invasive strategy.

展开